Drug Search Results
More Filters [+]

Mianserin

Alternative Names: mianserin
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT2 Antagonist,H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Chile | China | Cyprus | Czech | Denmark | Egypt | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Competence Centre for Transcultural Psychiatry
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mianserin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Parasomnias|Depressive Disorder|Dyssomnias

Phase 2: Stress Disorders, Post-Traumatic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2021-TX-002

P4

Recruiting

Parasomnias|Dyssomnias|Depressive Disorder

2025-12-01

PTF 5

P2

Completed

Stress Disorders, Post-Traumatic

2020-03-18

TECHUB2007

P4

Terminated

Depressive Disorder

2014-07-01

Recent News Events